Renalytix annual return on equity
2020
2021
2022
2023
Renalytix Return on Equity (ROE) Growth & History (RENX)
Renalytix's return on equity was −242.76% for fiscal 2023.
View full Renalytix company overviewRenalytix annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-06-30 | −242.76% | −154.04 pp |
| 2022 | 2022-06-30 | −88.72% | −7.83 pp |
| 2021 | 2021-06-30 | −80.89% | −0.40 pp |
| 2020 | 2020-06-30 | −80.48% | — |
Renalytix quarterly return on equity
Q3.22
Q1.23
Q3.23
Q4.23
Q1.24
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2024 | 2023-09-30 | −370.85% | −322.51 pp |
| Q4 2023 | 2023-06-30 | −88.61% | — |
| Q3 2023 | 2023-03-31 | −65.54% | −0.70 pp |
| Q1 2023 | 2022-09-30 | −48.34% | — |
| Q3 2022 | 2022-03-31 | −64.84% | — |
Renalytix return on equity trends
Between the periods ended 2020-06-30 and 2023-06-30, Renalytix's return on equity decreased from −80.48% to −242.76%, a change of −162.28 percentage points. The latest reported quarter, Q1 2024, shows −370.85%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Renalytix source filings ↗